A pioneering clinical study presented at the 2026 European Congress on Obesity (ECO2026) and published in Nature Medicine, reveals compelling evidence that most weight loss achieved through injectable medications for obesity can be effectively maintained by transitioning to a daily oral therapy. This breakthrough research, conducted by Dr. Louis J. Aronne and colleagues at Weill Cornell Medicine, explores a crucial challenge in obesity management — sustaining significant weight loss once achieved through potent injectable agents such as tirzepatide and semaglutide.
While the robust weight reduction effects of injectable GLP-1 receptor agonists and dual agonists have been well-documented, long-term adherence to these treatments often faces practical hurdles including injection aversion, cost considerations, and storage requirements. The current trial addresses the pressing clinical question of whether patients can successfully switch from injectable therapies to oral treatment modalities to maintain their weight loss, or if discontinuation of treatment leads to inevitable regain.
The clinical investigation enrolled participants from the earlier SURMOUNT-5 trial, in which obese patients achieved notable weight loss using either injectable tirzepatide or semaglutide. In this follow-up study, those individuals who reached weight loss plateaus were randomized in a double-blind, placebo-controlled manner to receive orforglipron, a newly FDA-approved oral GLP-1 receptor agonist, or placebo, for a period of one year following the conclusion of SURMOUNT-5.
Participants were divided into two cohorts based on their initial treatment: cohort 1 included 205 individuals previously treated with tirzepatide, and cohort 2 consisted of 171 participants formerly on semaglutide. Within these groups, randomization assigned 125 patients in cohort 1 and 105 in cohort 2 to receive orforglipron daily, while 80 and 66 patients respectively were given placebo. The dosing of orforglipron ranged between 24 and 36 mg daily, adjusted for individual tolerability.
Intriguingly, the results demonstrated that patients transitioned to orforglipron maintained a significantly greater proportion of their original weight loss compared to placebo recipients. Specifically, in the tirzepatide cohort, orforglipron maintained on average 74.7% of the lost weight from the SURMOUNT-5 baseline, whereas the placebo group maintained only 49.2%. Furthermore, nearly 44% of orforglipron-treated participants sustained at least 80% of their initial weight loss, more than doubling the 16% observed with placebo.
At the baseline of SURMOUNT-5, individuals in the first cohort had a mean body weight of approximately 116 kg. After the initial injectable therapy, their mean weight had reduced by about 21.5% prior to switching. Over the subsequent oral therapy phase, they experienced an additional maintenance of weight loss, culminating in a total reduction of 16.8% relative to their original baseline weight, equating to nearly 20 kilograms of net weight loss sustained over the entire trial period.
Comparable outcomes were observed in the semaglutide cohort. Participants receiving orforglipron maintained an impressive 79.3% of the weight lost during their injectable treatment phase, markedly higher than the 37.6% retention in the placebo arm. More than half of these patients preserved at least 80% of their prior weight loss, a staggering contrast to fewer than 7% in the placebo group. Baseline weights in this cohort averaged 113.5 kg, diminishing to 95.0 kg by the start of the oral therapy phase, and culminating in an overall loss of 15.1% across the entire study duration.
The trial further underscored the durability of cardiometabolic improvements associated with weight loss, noting that enhancements observed in cholesterol levels, blood pressure, and glycemic control throughout SURMOUNT-5 remained stable through the subsequent oral treatment period. Safety profiles were favorable, with comparable rates of adverse and serious adverse events between the orforglipron and placebo groups, supporting the tolerability of long-term oral GLP-1 receptor agonist therapy.
A unique aspect of this investigation was the implementation of a rescue therapy protocol. Participants initially assigned to placebo who exhibited a regain of 50% or more of their previously lost weight by 24 weeks were switched to orforglipron treatment. This strategy aimed to prevent complete reversal of the health gains realized during the initial injectable therapy and highlights the importance of dynamic, adaptive management strategies in chronic obesity care.
Analyzing weight trajectories, the authors observed differential patterns of weight regain contingent upon the initial injectable therapy. Those transitioning from the dual agonist tirzepatide experienced an average weight regain of 5 kg, or 5%, during the oral treatment phase, compared to only a modest 1 kg or 1% regain among patients who switched from semaglutide, a single GLP-1 receptor agonist. This suggests a complex interplay in receptor agonism and metabolic regulation warranting further mechanistic investigation.
Dr. Aronne and his team emphasize that although tirzepatide has demonstrated superior weight loss efficacy compared to semaglutide in head-to-head trials, the orforglipron oral regimen appeared particularly efficacious in sustaining the majority of weight loss post-semaglutide therapy. This finding illuminates the nuanced pharmacodynamic profiles of these agents and highlights the potential of oral GLP-1 receptor agonists to support maintenance therapy with greater patient convenience and adherence.
The study also challenges a pervasive misconception among both patients and healthcare providers: the assumption that obesity medications can be safely discontinued upon reaching target weight loss. The research underscores that cessation often provokes weight cycling and a resurgence of cardiometabolic risk factors, paralleling the chronic disease paradigm observed in hypertension and dyslipidemia management, where ongoing treatment is critical to maintaining health.
In conclusion, this landmark trial provides compelling evidence that transitioning from injectable obesity medications to an oral therapy like orforglipron is a viable and effective strategy to preserve weight loss and cardiometabolic benefits over the long term. It addresses critical barriers to persistence on injectable therapies, including patient preference, cost, and storage challenges, offering a promising pathway to improve real-world obesity outcomes through personalized and patient-centered treatment continuity.
Given the chronic nature of obesity, this research advocates for an integrated, shared decision-making approach that acknowledges individual variability in treatment response and preferences. It heralds a new era in obesity pharmacotherapy where oral agents not only facilitate initial weight reduction but also play a pivotal role in sustaining those hard-earned gains and minimizing relapse, thereby transforming the therapeutic landscape.
Subject of Research:
Maintenance of weight loss in obesity patients by switching from injectable therapies (tirzepatide or semaglutide) to oral orforglipron
Article Title:
Most Weight Loss Achieved with Injectable Obesity Drugs Maintained with Oral Orforglipron: Insights from the ATTAIN-MAINTAIN Trial
News Publication Date:
May 2026
Web References:
Study presented at ECO2026, Istanbul, Turkey; Article published in Nature Medicine
References:
Data derived from SURMOUNT-5 trial participants followed in ATTAIN-MAINTAIN trial; Full disclosures in original publication
Image Credits:
Not provided
Keywords:
Obesity, Weight loss maintenance, Tirzepatide, Semaglutide, Orforglipron, GLP-1 receptor agonist, Oral obesity treatment, Cardiometabolic health, Injectable to oral transition, Pharmacotherapy adherence
